News

June 5, 2017June 5, 2017

Genome Profiling May Help Predict Response to Keytruda in Head-Neck Cancer Patients

News

Profiling the genome of patients with head and neck squamous cell carcinoma (HNSCC) for mutations and interferon (IFN)-gamma-induced gene expression may independently predict patients’ response to immunotherapy with Keytruda (pembrolizumab), ... Read more

June 2, 2017June 6, 2017

Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients

News

Two immunotherapies, INO–5401 and INO–9012, will be combined with immune checkpoint inhibitor Tecentriq (atezolizumab) in a Phase 1/2 trial to test the combo’s safety and effectiveness in treating advanced bladder ... Read more

June 1, 2017

Intensity’s Treatment Candidate Administered to First Solid Tumor Patient in Phase 1/2 Trial

News

The first patient has successfully received treatment in a Phase 1/2 trial evaluating Intensity Therapeutics‘ drug candidate INT230-6 in different types of advanced solid tumors. The study will enroll up ... Read more

May 31, 2017

First Patient Dosed in Phase 2 Portion of Trial of X4P-001 Combo for Kidney Cancer

News

Researchers have dosed the first patient in the second part of a combined-phase clinical trial evaluating a combination of X4P-001 and Inlyta (axitinib) as a treatment for advanced kidney cancer. The trial ... Read more

May 30, 2017

Molecule Can Mask Cancer’s Pain, Helping the Disease Develop, Study Shows

News

The PD-L1 molecule can mask cancer’s pain, enabling malignancies to develop and spread without sending alarms to the immune system, according to a study. Researchers from Duke University School of ... Read more

May 26, 2017May 26, 2017

Rush Now Enrolling Patients in Phase 2 Trial Testing Opdivo Combo Therapies for Advanced Renal Cell Carcinoma

News

Chicago’s Rush University Medical Center is recruiting patients with advanced renal cell carcinoma for a Phase 2 trial to evaluate whether Opdivo (nivolumab) combined with other investigational immunotherapy drugs is more effective than the ... Read more

May 25, 2017May 25, 2017

FDA Chalks Up a First by Approving Keytruda for Cancers with Specific Genetic Features

News

In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. The ... Read more

May 24, 2017

FDA Grants Priority Review to Keytruda for Heavily-treated Stomach Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Licence Application (sBLA) seeking approval for Keytruda (pembrolizumab) to treat patients with recurrent or advanced gastric ... Read more

May 23, 2017

Nanoparticle Shows Promise in Engaging Immune System to Fight Tumors

News

The radio-enhancer nanoparticle NBTXR3, which is being developed to treat seven types of cancer, can effectively engage patients’ immune systems to fight cancer, transforming “cold” tumors into “hot” tumors. This ... Read more

May 22, 2017

FDA Approves Keytruda as First- and Second-Line Therapy for Bladder Cancer

News

The U.S. Food and Drug Administration has approved Merck’s anti-PD1 therapy Keytruda (pembrolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, or bladder cancer. Keytruda was granted accelerated ... Read more